Molecular Design: From Single Agonism to Dual Incretin Innovation
Novo Nordisk and Eli Lilly pursued fundamentally different molecular engineering philosophies to extend GLP-1 drug half-life and potency—a divergence that ultimately produced tirzepatide’s efficacy advantage. Novo Nordisk’s approach centered on progressive fatty acid acylation: liraglutide (approved 2009) used a C16 palmitoyl side chain enabling reversible albumin binding, achieving once-daily dosing with a half-life of approximately 13 hours and 97% homology to native GLP-1(7-37). Semaglutide (2017) upgraded to a C18 diacid fatty acid with stronger albumin binding and two amino acid substitutions (Aib8, Arg34), extending the half-life to approximately 165 hours—enabling once-weekly dosing—while maintaining 94% homology to native GLP-1.
Eli Lilly took a different route with dulaglutide (2014), using an IgG4 Fc fusion strategy: two GLP-1 analog molecules covalently linked to an IgG4 Fc fragment produce a large molecule of approximately 60 kDa. This large molecular weight reduces renal clearance and extends the half-life to approximately 4.5 days—achieving once-weekly dosing without any fatty acid acylation. The Fc-fusion platform represented a distinct molecular engineering route that avoided the albumin-binding mechanism entirely.
Tirzepatide (Eli Lilly, 2022) is the first approved dual GIP/GLP-1 receptor agonist. It activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors using a C20 fatty diacid for albumin binding, achieves a half-life of approximately 5 days enabling once-weekly dosing, and demonstrated up to 22.5% body weight reduction at 15 mg in Phase 3 SURMOUNT trials—compared to approximately 15% for semaglutide 2.4 mg.
Tirzepatide (2022) marked the paradigm shift. Rather than optimizing a single receptor pathway, Eli Lilly engineered a molecule that activates both GIP and GLP-1 receptors simultaneously. The dual mechanism—combined with a C20 fatty diacid for albumin binding—produced superior metabolic outcomes: HbA1c reductions of approximately 2.4% versus approximately 1.8% for semaglutide, and weight loss approaching bariatric surgery outcomes. This dual-agonist architecture is protected by patent PE0000492021A1 (filed 2020), covering GIP/GLP-1 agonist compositions for diabetes and obesity treatment, according to WIPO patent records.
Dual incretin agonism means a single molecule simultaneously activates two distinct receptor pathways: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Co-activation of both pathways produces greater insulin secretion, appetite suppression, and weight loss than GLP-1 monoagonism alone—tirzepatide’s mechanism of action and the source of its superior efficacy over semaglutide in head-to-head comparisons.
“Tirzepatide’s 22.5% weight loss approaches bariatric surgery outcomes—establishing a new benchmark that Novo Nordisk must match or exceed with next-generation molecules.”
Core Patent Landscape: IP Fortress vs. Focused Exclusivity
Novo Nordisk holds a broader, layered patent portfolio built over 15 years of continuous filings, while Eli Lilly’s IP strategy is concentrated on dual-agonist composition patents that carry the longest exclusivity runway in the class. Novo Nordisk’s patent fortress spans four distinct layers: composition of matter covering core GLP-1 analog structures with specific amino acid sequences and acylation patterns; formulation patents protecting stable compositions and oral delivery; method-of-use patents for cardiovascular risk reduction and weight management; and manufacturing process patents for solid-phase peptide synthesis. Key identified patents include WO2011073328A1 (semaglutide’s N-terminal modifications), US9993430B2 (oral semaglutide tablet formulation with SNAC co-formulation), WO2020084126A1 (stable semaglutide compositions), and EP3448416A1 (semaglutide for cardiovascular conditions).
Oral semaglutide (Novo Nordisk, approved 2019) was the first oral GLP-1 agonist approved, combining semaglutide with SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) as an absorption enhancer. The tablet formulation is protected by patent US9993430B2. Semaglutide core patents expire approximately 2031–2033; liraglutide core patents expired or are expiring 2023–2025, opening the door to biosimilar competition.
Eli Lilly’s focused strategy emphasizes three IP pillars: dual-agonist composition patents covering GIP/GLP-1 co-agonist peptide structures (tirzepatide core IP in PE0000492021A1, filed 2020); combination therapy patents for GIP/GLP-1 agonists with other metabolic agents; and device patents covering single-dose auto-injector mechanisms. Because tirzepatide entered the market in 2022—eight years after semaglutide’s 2017 approval—its core patents carry an exclusivity runway extending to approximately 2036–2038, versus semaglutide’s ~2031–2033 expiry. This timing difference is strategically significant: Lilly’s later entry translates directly into longer market exclusivity, as tracked by EPO patent family records.
Third-party patent activity signals intense competitive interest: biosimilar and generic manufacturers including Enzene Biosciences and Hybio Pharma are filing process patents for GLP-1 synthesis. Combination therapy patents from other pharmaceutical companies explore GLP-1 plus SGLT2 inhibitor and GLP-1 plus DPP-4 inhibitor combinations. Smaller biotech companies are filing novel delivery patents for oral, sublingual, and transdermal GLP-1 delivery—a landscape tracked by patent databases at the USPTO.
Map the full GLP-1 patent landscape and identify freedom-to-operate risks with PatSnap Eureka’s AI-powered patent analysis.
Explore GLP-1 Patents in PatSnap Eureka →Clinical Program Scale and Efficacy Benchmarks
Novo Nordisk’s clinical program is the largest in GLP-1 history, but Eli Lilly’s focused superiority trials have redefined the efficacy ceiling. Novo Nordisk has conducted 188 Phase 3 trials for liraglutide and semaglutide, spanning diabetes, obesity, and cardiovascular indications—including the landmark LEADER trial (liraglutide, 13% reduction in major adverse cardiovascular events), SUSTAIN and STEP programs, and recent trials in chronic kidney disease and NASH. Eli Lilly has run 68 Phase 3 trials for dulaglutide and tirzepatide, with the SURMOUNT program for tirzepatide obesity and the SUMMIT trial demonstrating benefit in heart failure with preserved ejection fraction (HFpEF).
In pivotal Phase 3 trials, tirzepatide 15 mg achieved approximately 22.5% body weight reduction and approximately 2.4% HbA1c reduction. Semaglutide 2.4 mg achieved approximately 15% body weight reduction and approximately 1.8% HbA1c reduction. Liraglutide 3.0 mg achieved approximately 8% body weight reduction. Dulaglutide 4.5 mg achieved approximately 10% body weight reduction and approximately 1.5% HbA1c reduction.
Both companies have expanded into pediatric obesity and diabetes. Novo Nordisk is conducting semaglutide trials in adolescents aged 12 and older. Eli Lilly’s SURMOUNT-ADOLESCENTS program evaluates tirzepatide in adolescents. Emerging indications include obstructive sleep apnea (SURMOUNT-OSA for tirzepatide), HFpEF (SUMMIT trial for tirzepatide), inflammatory conditions, and type 1 diabetes adjunctive therapy—broadening the addressable market well beyond the original type 2 diabetes indication.
Cardiovascular outcomes trial results are increasingly essential for payer coverage. The LEADER trial (liraglutide) showed a 13% reduction in MACE; the SELECT trial (semaglutide) showed a 20% reduction; the REWIND trial (dulaglutide) showed a 12% reduction. The SUMMIT trial for tirzepatide demonstrated benefit in heart failure with preserved ejection fraction—a distinct cardiovascular endpoint positioning tirzepatide in the heart failure market.
Drug Delivery Innovation: Pens, Oral Tablets, and Adherence
Delivery device innovation became a primary competitive battleground once weekly dosing was achieved by both companies, with each targeting different patient segments based on injection comfort. Novo Nordisk’s formulation evolution progressed from liraglutide’s aqueous solution (pH ~8.15) with disodium phosphate dihydrate, propylene glycol, and phenol preservative, to semaglutide injectable’s improved stability formulation enabling 56-day room-temperature storage after first use. The most significant delivery breakthrough was oral semaglutide (2019): a tablet combining semaglutide with SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) absorption enhancer—the first oral GLP-1 agonist approved, protected by patent US9993430B2.
Eli Lilly’s delivery differentiation focused on injection-averse patients. The Trulicity single-dose pen introduced the first auto-injector with a hidden needle and one-button activation—no dose selection or priming required. The Mounjaro/Zepbound KwikPen maintained this auto-injector design with color-coded dose strengths across six doses (2.5, 5, 7.5, 10, 12.5, and 15 mg). Novo Nordisk’s FlexTouch prefilled pen uses a dial-a-dose mechanism with audible click confirmation and no priming, targeting patients comfortable with injections; Lilly’s auto-injector targets injection-averse patients through spring-driven automatic injection with a pre-attached hidden needle.
Dulaglutide’s phosphate-buffered solution (pH ~5) with mannitol and polysorbate 80 is stable for 14 days at room temperature; tirzepatide uses a similar buffered solution with enhanced stability for single-dose pen storage. Both formulation strategies prioritize supply chain simplicity and patient convenience outside clinical settings, as documented in regulatory submissions tracked by the FDA.
Track drug delivery patent filings and formulation IP trends across the GLP-1 competitive landscape in real time.
Analyse Delivery Patents in PatSnap Eureka →Technology Roadmap Outlook 2024–2026
The 2024–2026 period is defined by the race toward oral formulations, triple agonism, and extended-duration delivery—with both companies leveraging distinct technological strengths to maintain competitive positioning. Novo Nordisk is advancing CagriSema (semaglutide combined with cagrilintide, an amylin analog) in Phase 3, targeting more than 25% weight loss—which would exceed tirzepatide’s current benchmark. Higher-dose oral semaglutide is also in development. Eli Lilly is developing orforglipron, an oral GLP-1 agonist in Phase 3, and retatrutide—a triple GIP/GLP-1/glucagon agonist in Phase 2/3 that represents the next potential efficacy leap beyond dual agonism.
| Dimension | Novo Nordisk | Eli Lilly |
|---|---|---|
| Core molecular strategy | GLP-1 monoagonist optimization (fatty acid acylation) | Fc-fusion → Dual GIP/GLP-1 agonism → Triple agonism |
| Phase 3 trial scale | 188 trials | 68 trials |
| Best-in-class weight loss | ~15% (semaglutide 2.4 mg) | ~22.5% (tirzepatide 15 mg) |
| Oral formulation | Approved (oral semaglutide, 2019) | Phase 3 (orforglipron) |
| Next-gen pipeline | CagriSema (Phase 3, >25% target) | Retatrutide (triple agonist, Phase 2/3) |
| Longest patent exclusivity | Semaglutide ~2031–2033 | Tirzepatide ~2036–2038 |
| Biosimilar exposure | Liraglutide (near-term, 2023–2025) | Dulaglutide (~2027–2029) |
Patent expiration dynamics create diverging near-term pressures. Liraglutide core patents expired or are expiring 2023–2025, opening the door to biosimilar entry—with peptide synthesis process optimization and formulation stability identified as key technical hurdles for biosimilar manufacturers. Dulaglutide core patents expire approximately 2027–2029. Semaglutide core patents expire approximately 2031–2033. Tirzepatide, as the most recent entrant, carries the longest exclusivity runway to approximately 2036–2038—a direct consequence of Lilly’s later market entry strategy. Innovation intelligence platforms like PatSnap’s patent analytics suite enable monitoring of these expiry timelines and emerging biosimilar filings in real time.
“The ultimate winner will be determined by which company first delivers an oral, once-monthly, more-than-25% weight-loss agent with proven cardiovascular benefit—a race both are actively pursuing.”
For biosimilar and generic entrants, liraglutide represents the near-term opportunity. For innovators competing in the GLP-1 space, tirzepatide’s success demonstrates that superior weight loss exceeding 20% can overcome first-mover advantage—a finding with direct implications for R&D prioritization, as documented in PatSnap’s pharmaceutical innovation research. Cardiovascular outcomes data has become essential for payer coverage decisions, and device innovation—particularly hidden-needle auto-injectors—continues to drive adherence and patient acceptance in this multi-billion-dollar market.
Eli Lilly is developing retatrutide, a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 2/3 trials, as the next potential efficacy advance beyond tirzepatide’s dual agonism. Novo Nordisk is developing CagriSema—semaglutide combined with cagrilintide, an amylin analog—in Phase 3 trials targeting more than 25% weight loss, which would exceed tirzepatide’s current 22.5% benchmark if achieved.